Medical cannabis vs. synthetic cannabinoids: What does the future hold? | Zendy

Bolognini D | Zendy; Ross RA | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Medical cannabis vs. synthetic cannabinoids: What does the future hold?

Author(s) -

Bolognini D,

Ross RA

Publication year - 2015

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1002/cpt.107

Subject(s) - synthetic cannabinoids , cannabis , cannabinoid , cannabinoid receptor , tetrahydrocannabinol , pharmacology , dronabinol , medicine , chemistry , receptor , psychiatry , agonist

The medical use of cannabis has an intricate therapeutic history that finds its roots in ancient China (∼2700 BC). The main psychoactive component of cannabis, Δ 9 ‐tetrahydrocannabinol (Δ 9 ‐THC), was discovered in 1964. This was a significant breakthrough, as it allowed the generation of synthetic analogs of Δ 9 ‐THC, the discovery of cannabinoid receptors, and the generation of synthetic small molecules. Despite this, today there is still a paucity of drugs that target the cannabinoid system.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research